Indi Molecular Revenue and Competitors
Estimated Revenue & Valuation
- Indi Molecular's estimated annual revenue is currently $620k per year.
- Indi Molecular's estimated revenue per employee is $155,000
Employee Data
- Indi Molecular has 4 Employees.
- Indi Molecular grew their employee count by -20% last year.
Indi Molecular's People
| Name | Title | Email/Phone |
|---|
Indi Molecular Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is Indi Molecular?
Indi Molecular is developing protein catalyzed capture (PCC) agents as a small synthetic molecule replacement for antibody-based therapeutics. PCCs are poised to play a central role in therapy given their ability to be deployed as both a precision in vivo PET diagnostic and as a targeted therapeutic. For radiotherapy this dual role is accomplished by choice of the complexed radionuclide sharing the same chelation chemistry. Chemotherapy can similarly be specifically delivered to diseased cells by the protein catalyzed capture technology. The company launched in 2013 with a $1.8 million seed round, followed by an $11.5 million Series A in 2017.
keywords:N/A
N/A
Total Funding
4
Number of Employees
$620k
Revenue (est)
-20%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Culver City
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $0.3M | 4 | -20% | N/A |
#2 | $0.3M | 4 | N/A | N/A |
#3 | $0.3M | 4 | 33% | N/A |
#4 | $0.3M | 4 | 0% | N/A |
#5 | $0.1M | 4 | -20% | N/A |